Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 871 Präparate · 48256 Quellenpassagen · 124 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Viagra
VIAGRA 25 mg film-coated tablets VIAGRA 50 mg film-coated tablets VIAGRA 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7
HOS-088799 · Präparat HOS-083727
Concomitant administration of sildenafil to patients taking alpha-blocker therapy may lead to
symptomatic hypotension in a few susceptible individuals. This is most likely to occur within 4 hours
post sildenafil dosing (see sections 4.2 and 4.4). In three specific drug-drug interaction studies, the
alpha-blocker doxazosin (4 mg and 8 mg) and sildenafil (25 mg, 50 mg, or 100 mg) were administered
simultaneously to patients with benign prostatic hyperplasia (BPH) stabilized on doxazosin therapy. In
these study populations, mean additional reductions of supine blood pressure of 7/7 mmHg,
9/5 mmHg, and 8/4 mmHg, and mean additional reductions of standing blood pressure of 6/6 mmHg,
11/4 mmHg, and 4/5 mmHg, respectively, were observed. When sildenafil and doxazosin were
administered simultaneously to patients stabilized on doxazosin therapy, there were infrequent reports
of patients who experienced symptomatic postural hypotension. These reports included dizziness and
light-headedness, but not syncope.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lead (HOS-085592) doxazosin (HOS-088800)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-13T10:49:00Z · SHA-256 6ad3c46b09a0a4a504f9373ab6370260a3b70fd305f7a7b80959175ca84b454e · Passage 711bfff2b0d0c3eb5f18a8052209d238d91d9092bec736b81080210041fff983 · Zeichen 5500–6512 im Abschnitt
Wechselwirkungen · Viagra
VIAGRA 50 mg orodispersible tablets · Abschnitt 4.5 · PDF-Seite 20–21
HOS-088855 · Präparat HOS-083727
Riociguat: Preclinical studies showed additive systemic blood pressure lowering effect when PDE5
inhibitors were combined with riociguat. In clinical studies, riociguat has been shown to augment the
hypotensive effects of PDE5 inhibitors. There was no evidence of favourable clinical effect of the
combination in the population studied. Concomitant use of riociguat with PDE5 inhibitors, including
sildenafil, is contraindicated (see section 4.3).
20
Concomitant administration of sildenafil to patients taking alpha-blocker therapy may lead to
symptomatic hypotension in a few susceptible individuals. This is most likely to occur within 4 hours
post sildenafil dosing (see sections 4.2 and 4.4). In three specific drug-drug interaction studies, the
alpha-blocker doxazosin (4 mg and 8 mg) and sildenafil (25 mg, 50 mg, or 100 mg) were administered
simultaneously to patients with benign prostatic hyperplasia (BPH) stabilized on doxazosin therapy. In
these study populations, mean additional reductions of supine blood pressure of 7/7 mmHg,
9/5 mmHg, and 8/4 mmHg, and mean additional reductions of standing blood pressure of 6/6 mmHg,
11/4 mmHg, and 4/5 mmHg, respectively, were observed. When sildenafil and doxazosin were
administered simultaneously to patients stabilized on doxazosin therapy, there were infrequent reports
of patients who experienced symptomatic postural hypotension. These reports included dizziness and
light-headedness, but not syncope.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): riociguat (HOS-086293) lead (HOS-085592) doxazosin (HOS-088800)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-13T10:49:00Z · SHA-256 6ad3c46b09a0a4a504f9373ab6370260a3b70fd305f7a7b80959175ca84b454e · Passage b828f8947fcc03e3016c59c4b438ec2d0048266fb83b7e546a68a4e887ecc849 · Zeichen 5054–6570 im Abschnitt
Wechselwirkungen · Viagra
VIAGRA 50 mg orodispersible films · Abschnitt 4.5 · PDF-Seite 34–35
HOS-088906 · Präparat HOS-083727
Concomitant administration of sildenafil to patients taking alpha-blocker therapy may lead to
symptomatic hypotension in a few susceptible individuals. This is most likely to occur within 4 hours
34
post sildenafil dosing (see sections 4.2 and 4.4). In three specific drug-drug interaction studies, the
alpha-blocker doxazosin (4 mg and 8 mg) and sildenafil (25 mg, 50 mg, or 100 mg) were administered
simultaneously to patients with benign prostatic hyperplasia (BPH) stabilized on doxazosin therapy. In
these study populations, mean additional reductions of supine blood pressure of 7/7 mmHg,
9/5 mmHg, and 8/4 mmHg, and mean additional reductions of standing blood pressure of 6/6 mmHg,
11/4 mmHg, and 4/5 mmHg, respectively, were observed. When sildenafil and doxazosin were
administered simultaneously to patients stabilized on doxazosin therapy, there were infrequent reports
of patients who experienced symptomatic postural hypotension. These reports included dizziness and
light-headedness, but not syncope.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lead (HOS-085592) doxazosin (HOS-088800)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-13T10:49:00Z · SHA-256 6ad3c46b09a0a4a504f9373ab6370260a3b70fd305f7a7b80959175ca84b454e · Passage 932582cb7cc2322730690119de4f4ff689c91448f308fb14d34667683466a2a1 · Zeichen 5501–6569 im Abschnitt
Wechselwirkungen · Cialis
CIALIS 2.5 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6
HOS-111255 · Präparat HOS-093485
Anti-hypertensives (including calcium channel blockers)
The co-administration of doxazosin (4 and 8 mg daily) and tadalafil (5 mg daily dose and 20 mg as a
single dose) increases the blood pressure-lowering effect of this alpha-blocker in a significant manner.
This effect lasts at least twelve hours and may be symptomatic, including syncope. Therefore this
combination is not recommended (see section 4.4).
In interaction studies performed in a limited number of healthy volunteers, these effects were not
reported with alfuzosin or tamsulosin. However, caution should be exercised when using tadalafil in
patients treated with any alpha-blockers, and notably in the elderly. Treatments should be initiated at
minimal dosage and progressively adjusted.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): calcium (HOS-085615) doxazosin (HOS-088800) alfuzosin (HOS-086139) tamsulosin (HOS-111257)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-28T14:23:00Z · SHA-256 545fdb0c46550348a52d431b0929b4f86d6314f2661c3c334d55f57753aad337 · Passage cabfad89c45f22b6c41a39f145cc850ce5c6ddf73cc1063f85fcb928cb8d0481 · Zeichen 2943–3697 im Abschnitt
Wechselwirkungen · Cialis
CIALIS 5 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 20–21
HOS-111302 · Präparat HOS-093485
20
Anti-hypertensives (including calcium channel blockers)
The co-administration of doxazosin (4 and 8 mg daily) and tadalafil (5 mg daily dose and 20 mg as a
single dose) increases the blood pressure-lowering effect of this alpha-blocker in a significant manner.
This effect lasts at least twelve hours and may be symptomatic, including syncope. Therefore this
combination is not recommended (see section 4.4).
In interaction studies performed in a limited number of healthy volunteers, these effects were not
reported with alfuzosin or tamsulosin. However, caution should be exercised when using tadalafil in
patients treated with any alpha-blockers, and notably in the elderly. Treatments should be initiated at
minimal dosage and progressively adjusted.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): calcium (HOS-085615) doxazosin (HOS-088800) alfuzosin (HOS-086139) tamsulosin (HOS-111257)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-28T14:23:00Z · SHA-256 545fdb0c46550348a52d431b0929b4f86d6314f2661c3c334d55f57753aad337 · Passage 999d333c830ddb852b21bf2047f283bfeae5cc46ae36b00f2f883395cebd5d4c · Zeichen 2942–3700 im Abschnitt
Wechselwirkungen · Cialis
CIALIS 10 mg film-coated tablets CIALIS 20 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 35
HOS-111341 · Präparat HOS-093485
Anti-hypertensives (including calcium channel blockers)
The co-administration of doxazosin (4 and 8 mg daily) and tadalafil (5 mg daily dose and 20 mg as a
single dose) increases the blood pressure-lowering effect of this alpha-blocker in a significant manner.
This effect lasts at least twelve hours and may be symptomatic, including syncope. Therefore this
combination is not recommended (see section 4.4).
In interaction studies performed in a limited number of healthy volunteers, these effects were not
reported with alfuzosin or tamsulosin. However, caution should be exercised when using tadalafil in
patients treated with any alpha-blockers, and notably in the elderly. Treatments should be initiated at
minimal dosage and progressively adjusted.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): calcium (HOS-085615) doxazosin (HOS-088800) alfuzosin (HOS-086139) tamsulosin (HOS-111257)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-28T14:23:00Z · SHA-256 545fdb0c46550348a52d431b0929b4f86d6314f2661c3c334d55f57753aad337 · Passage cabfad89c45f22b6c41a39f145cc850ce5c6ddf73cc1063f85fcb928cb8d0481 · Zeichen 2946–3700 im Abschnitt
Wechselwirkungen · Revatio
Revatio 20 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 8
HOS-114953 · Präparat HOS-094193
In three specific drug-drug interaction studies, the alpha-blocker doxazosin (4 mg and 8 mg) and
sildenafil (25 mg, 50 mg, or 100 mg) were administered simultaneously to patients with benign
prostatic hyperplasia (BPH) stabilized on doxazosin therapy. In these study populations, mean
additional reductions of supine systolic and diastolic blood pressure of 7/7 mmHg, 9/5 mmHg, and
8/4 mmHg, respectively, and mean additional reductions of standing blood pressure of 6/6 mmHg,
11/4 mmHg, and 4/5 mmHg, respectively were observed. When sildenafil and doxazosin were
administered simultaneously to patients stabilized on doxazosin therapy, there were infrequent reports
of patients who experienced symptomatic postural hypotension. These reports included dizziness and
lightheadedness, but not syncope. Concomitant administration of sildenafil to patients taking
alpha-blocker therapy may lead to symptomatic hypotension in susceptible individuals (see section
4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lead (HOS-085592) doxazosin (HOS-088800)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-13T14:12:00Z · SHA-256 38afb4f2877b63c9a3d5213ff8cb4458ff9d43618600f9ce01caed1bd5a4764f · Passage 14be1b2f7f9bdf4d88008c516b2997ace4c575593a1757a4a2098a060188e12d · Zeichen 8515–9479 im Abschnitt
Wechselwirkungen · Revatio
Revatio 0.8 mg/ml solution for injection · Abschnitt 4.5 · PDF-Seite 28
HOS-115016 · Präparat HOS-094193
In three specific drug-drug interaction studies, the alpha-blocker doxazosin (4 mg and 8 mg) and oral
sildenafil (25 mg, 50 mg, or 100 mg) were administered simultaneously to patients with benign
prostatic hyperplasia (BPH) stabilized on doxazosin therapy. In these study populations, mean
additional reductions of supine systolic and diastolic blood pressure of 7/7 mmHg, 9/5 mmHg, and
8/4 mmHg, respectively, and mean additional reductions of standing blood pressure of 6/6 mmHg,
11/4 mmHg, and 4/5 mmHg, respectively were observed. When sildenafil and doxazosin were
administered simultaneously to patients stabilized on doxazosin therapy, there were infrequent reports
of patients who experienced symptomatic postural hypotension. These reports included dizziness and
lightheadedness, but not syncope. Concomitant administration of sildenafil to patients taking
alpha-blocker therapy may lead to symptomatic hypotension in susceptible individuals (see section
4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): doxazosin (HOS-088800) lead (HOS-085592)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-13T14:12:00Z · SHA-256 38afb4f2877b63c9a3d5213ff8cb4458ff9d43618600f9ce01caed1bd5a4764f · Passage 9f60aa292145c8703655e91205ca94757dadf404d84725263fb6011b7fada63a · Zeichen 9348–10317 im Abschnitt
Wechselwirkungen · Revatio
Revatio 10 mg/ml powder for oral suspension · Abschnitt 4.5 · PDF-Seite 46
HOS-115074 · Präparat HOS-094193
In three specific drug-drug interaction studies, the alpha-blocker doxazosin (4 mg and 8 mg) and
sildenafil (25 mg, 50 mg, or 100 mg) were administered simultaneously to patients with benign
prostatic hyperplasia (BPH) stabilized on doxazosin therapy. In these study populations, mean
additional reductions of supine systolic and diastolic blood pressure of 7/7 mmHg, 9/5 mmHg, and
8/4 mmHg, respectively, and mean additional reductions of standing blood pressure of 6/6 mmHg,
11/4 mmHg, and 4/5 mmHg, respectively were observed. When sildenafil and doxazosin were
administered simultaneously to patients stabilized on doxazosin therapy, there were infrequent reports
of patients who experienced symptomatic postural hypotension. These reports included dizziness and
lightheadedness, but not syncope. Concomitant administration of sildenafil to patients taking
alpha-blocker therapy may lead to symptomatic hypotension in susceptible individuals (see section
4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): doxazosin (HOS-088800) lead (HOS-085592)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-13T14:12:00Z · SHA-256 38afb4f2877b63c9a3d5213ff8cb4458ff9d43618600f9ce01caed1bd5a4764f · Passage 14be1b2f7f9bdf4d88008c516b2997ace4c575593a1757a4a2098a060188e12d · Zeichen 8518–9482 im Abschnitt
Wechselwirkungen · Sildenafil ratiopharm
Sildenafil ratiopharm 25 mg film-coated tablets Sildenafil ratiopharm 50 mg film-coated tablets Sildenafil ratiopharm 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6
HOS-121696 · Präparat HOS-095413
Concomitant administration of sildenafil to patients taking alpha-blocker therapy may lead to
symptomatic hypotension in a few susceptible individuals. This is most likely to occur within 4 hours
post sildenafil dosing (see sections 4.2 and 4.4). In three specific drug-drug interaction studies, the
alpha-blocker doxazosin (4 mg and 8 mg) and sildenafil (25 mg, 50 mg, or 100 mg) were administered
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lead (HOS-085592) doxazosin (HOS-088800)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2022-06-24T11:00:00Z · SHA-256 c808d2606faf49a55ff479538c23c7b32973eab6a82cf87d69b7ee7085cb369e · Passage 105f7318ce54dafe8516e2f46fecd0361f98290214e18f89df22c65dbdf64c1e · Zeichen 5503–5901 im Abschnitt
Wechselwirkungen · Sildenafil ratiopharm
Sildenafil ratiopharm 25 mg film-coated tablets Sildenafil ratiopharm 50 mg film-coated tablets Sildenafil ratiopharm 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6–7
HOS-121698 · Präparat HOS-095413
6
simultaneously to patients with benign prostatic hyperplasia (BPH) stabilized on doxazosin therapy. In
these study populations, mean additional reductions of supine blood pressure of 7/7 mmHg,
9/5 mmHg, and 8/4 mmHg, and mean additional reductions of standing blood pressure of 6/6 mmHg,
11/4 mmHg, and 4/5 mmHg, respectively, were observed. When sildenafil and doxazosin were
administered simultaneously to patients stabilized on doxazosin therapy, there were infrequent reports
of patients who experienced symptomatic postural hypotension. These reports included dizziness and
light-headedness, but not syncope.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): doxazosin (HOS-088800)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2022-06-24T11:00:00Z · SHA-256 c808d2606faf49a55ff479538c23c7b32973eab6a82cf87d69b7ee7085cb369e · Passage 76246c362e453c26cfd82aaad526434b66cd27870612e934898aa2f13c01579b · Zeichen 5955–6571 im Abschnitt
Wechselwirkungen · Spedra
Spedra 50 mg tablets · Abschnitt 4.5 · PDF-Seite 5
HOS-127417 · Präparat HOS-096405
Alpha-blockers
Haemodynamic interactions with doxazosin and tamsulosin were studied in healthy subjects in a two-
period crossover-design trial. In patients receiving stable doxazosin treatment, the placebo-subtracted
mean maximum decreases in standing and supine systolic blood pressure following avanafil dosing
were 2.5 mmHg and 6.0 mmHg, respectively. In total, 7/24 subjects experienced values or decreases
from baseline that were of potential clinical significance following avanafil dosing (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): doxazosin (HOS-088800) tamsulosin (HOS-111257)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-07T15:55:00Z · SHA-256 9f3a1264ef001d577393feb260b99952ed079148f452f8976f0be132f469d380 · Passage 781951c4a84396b722df6625324ef3fe68b1dc5aa776052dc10bdbb216df66af · Zeichen 1712–2227 im Abschnitt
Wechselwirkungen · Spedra
Spedra 100 mg tablets · Abschnitt 4.5 · PDF-Seite 18
HOS-127462 · Präparat HOS-096405
Alpha-blockers
Haemodynamic interactions with doxazosin and tamsulosin were studied in healthy subjects in a two-
period crossover-design trial. In patients receiving stable doxazosin treatment, the placebo-subtracted
mean maximum decreases in standing and supine systolic blood pressure following avanafil dosing
were 2.5 mmHg and 6.0 mmHg, respectively. In total, 7/24 subjects experienced values or decreases
from baseline that were of potential clinical significance following avanafil dosing (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): doxazosin (HOS-088800) tamsulosin (HOS-111257)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-07T15:55:00Z · SHA-256 9f3a1264ef001d577393feb260b99952ed079148f452f8976f0be132f469d380 · Passage 781951c4a84396b722df6625324ef3fe68b1dc5aa776052dc10bdbb216df66af · Zeichen 1712–2227 im Abschnitt
Wechselwirkungen · Spedra
Spedra 200 mg tablets · Abschnitt 4.5 · PDF-Seite 31
HOS-127506 · Präparat HOS-096405
Alpha-blockers
Haemodynamic interactions with doxazosin and tamsulosin were studied in healthy subjects in a two-
period crossover-design trial. In patients receiving stable doxazosin treatment, the placebo-subtracted
mean maximum decreases in standing and supine systolic blood pressure following avanafil dosing
were 2.5 mmHg and 6.0 mmHg, respectively. In total, 7/24 subjects experienced values or decreases
from baseline that were of potential clinical significance following avanafil dosing (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): doxazosin (HOS-088800) tamsulosin (HOS-111257)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-07T15:55:00Z · SHA-256 9f3a1264ef001d577393feb260b99952ed079148f452f8976f0be132f469d380 · Passage 781951c4a84396b722df6625324ef3fe68b1dc5aa776052dc10bdbb216df66af · Zeichen 1712–2227 im Abschnitt
Wechselwirkungen · Tadalafil Mylan
Tadalafil Mylan 2.5 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6
HOS-131383 · Präparat HOS-097067
Anti-hypertensives (including calcium channel blockers)
The co-administration of doxazosin (4 and 8 mg daily) and tadalafil (5 mg daily dose and 20 mg as a single
dose) increases the blood pressure-lowering effect of this alpha-blocker in a significant manner. This effect
lasts at least twelve hours and may be symptomatic, including syncope. Therefore this combination is not
recommended (see section 4.4).
In interaction studies performed in a limited number of healthy volunteers, these effects were not reported
with alfuzosin or tamsulosin. However, caution should be exercised when using tadalafil in patients treated
with any alpha-blockers, and notably in the elderly. Treatments should be initiated at minimal dosage and
progressively adjusted.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): calcium (HOS-085615) doxazosin (HOS-088800) alfuzosin (HOS-086139) tamsulosin (HOS-111257)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-15T12:38:00Z · SHA-256 2c06d7b4e73c05361baf5d12e4bb06aa9f06b0ce1a899ac34068fb6b554e7343 · Passage c3c3d88656ecc7871d91497d3c32df63d4e2516ff6ce69cf832c78c00752eb7e · Zeichen 2954–3708 im Abschnitt
Wechselwirkungen · Tadalafil Mylan
Tadalafil Mylan 5 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 20
HOS-131432 · Präparat HOS-097067
Anti-hypertensives (including calcium channel blockers)
The co-administration of doxazosin (4 and 8 mg daily) and tadalafil (5 mg daily dose and 20 mg as a single
dose) increases the blood pressure-lowering effect of this alpha-blocker in a significant manner. This effect
lasts at least twelve hours and may be symptomatic, including syncope. Therefore this combination is not
recommended (see section 4.4).
In interaction studies performed in a limited number of healthy volunteers, these effects were not reported
with alfuzosin or tamsulosin. However, caution should be exercised when using tadalafil in patients treated
with any alpha-blockers, and notably in the elderly. Treatments should be initiated at minimal dosage and
progressively adjusted.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): calcium (HOS-085615) doxazosin (HOS-088800) alfuzosin (HOS-086139) tamsulosin (HOS-111257)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-15T12:38:00Z · SHA-256 2c06d7b4e73c05361baf5d12e4bb06aa9f06b0ce1a899ac34068fb6b554e7343 · Passage c3c3d88656ecc7871d91497d3c32df63d4e2516ff6ce69cf832c78c00752eb7e · Zeichen 2894–3648 im Abschnitt
Wechselwirkungen · Tadalafil Mylan
Tadalafil Mylan 10 mg film-coated tablets Tadalafil Mylan 20 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 35
HOS-131478 · Präparat HOS-097067
Anti-hypertensives (including calcium channel blockers)
The co-administration of doxazosin (4 and 8 mg daily) and tadalafil (5 mg daily dose and 20 mg as a single
dose) increases the blood pressure-lowering effect of this alpha-blocker in a significant manner. This effect
lasts at least twelve hours and may be symptomatic, including syncope. Therefore this combination is not
recommended (see section 4.4).
In interaction studies performed in a limited number of healthy volunteers, these effects were not reported
with alfuzosin or tamsulosin. However, caution should be exercised when using tadalafil in patients treated
with any alpha-blockers, and notably in the elderly. Treatments should be initiated at minimal dosage and
progressively adjusted.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): calcium (HOS-085615) doxazosin (HOS-088800) alfuzosin (HOS-086139) tamsulosin (HOS-111257)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-15T12:38:00Z · SHA-256 2c06d7b4e73c05361baf5d12e4bb06aa9f06b0ce1a899ac34068fb6b554e7343 · Passage c3c3d88656ecc7871d91497d3c32df63d4e2516ff6ce69cf832c78c00752eb7e · Zeichen 2952–3706 im Abschnitt
Wechselwirkungen · Talmanco (previously Tadalafil Generics)
Talmanco 20 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6–7
HOS-137542 · Präparat HOS-098059
6
Anti-hypertensives (including Calcium channel blockers)
The co-administration of doxazosin (4 and 8 mg daily) and tadalafil (5 mg daily dose and 20 mg as a
single dose) increases the blood pressure-lowering effect of this alpha-blocker in a significant manner.
This effect lasts at least twelve hours and may be symptomatic, including syncope. Therefore, this
combination is not recommended (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): calcium (HOS-085615) doxazosin (HOS-088800)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-05-08T02:00:00Z · SHA-256 9416206846678eeb980d8118e3703862499194c0ef267c815ee4a68563143115 · Passage 6f6610b04ac27352beb959716082bece2c6e94a698d24e7e863226fa7fbb820a · Zeichen 2083–2495 im Abschnitt
Wechselwirkungen · Talmanco (previously Tadalafil Generics)
Talmanco 20 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7
HOS-137546 · Präparat HOS-098059
In clinical pharmacology studies, the potential for tadalafil (10 and 20 mg) to augment the hypotensive
effects of antihypertensive medicinal products was examined. Major classes of antihypertensive
medicinal products were studied either as monotherapy or as part of combination therapy. In patients
taking multiple antihypertensive medicinal products whose hypertension was not well controlled,
greater reductions in blood pressure were observed compared to patients whose blood pressure was
well controlled, where the reduction was minimal and similar to that in healthy subjects. In patients
receiving concomitant antihypertensive medicinal products, tadalafil 20 mg may induce a blood
pressure decrease, which (with the exception of doxazosin -see above) is, in general, minor and not
likely to be clinically relevant.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): doxazosin (HOS-088800)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-05-08T02:00:00Z · SHA-256 9416206846678eeb980d8118e3703862499194c0ef267c815ee4a68563143115 · Passage 77318abb2637775f71aa94cf8e16fae0a92d6dda97a320ccfa6febd837b8dc5d · Zeichen 2636–3458 im Abschnitt
Wechselwirkungen · Tadalafil Lilly
Tadalafil Lilly 2.5 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6
HOS-140426 · Präparat HOS-098526
Anti-hypertensives (including calcium channel blockers)
The co-administration of doxazosin (4 and 8 mg daily) and tadalafil (5 mg daily dose and 20 mg as a
single dose) increases the blood pressure-lowering effect of this alpha-blocker in a significant manner.
This effect lasts at least twelve hours and may be symptomatic, including syncope. Therefore this
combination is not recommended (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): calcium (HOS-085615) doxazosin (HOS-088800)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-28T13:35:00Z · SHA-256 591c030e92917080839aac0522f89e39ae339bcc4be9e68371f7969a185b0857 · Passage eed3a67e714f5b27764d734e1e0ecbb213327d16cfbfd8e2b012c1b2453eaa2c · Zeichen 2988–3396 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.